MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.
Study Type
OBSERVATIONAL
Enrollment
500
Immunosuppression protocol with enteric-coated mycophenolate sodium
Immunosuppression protocol without enteric-coated mycophenolate sodium
Third Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
RECRUITINGcomplex endpoint
Graft loss or reoccurrence of HCC, or neoplasm, or death
Time frame: 60 months after liver transplantation
Late onset acute rejection
rejection diagnosed by liver test, pathologic diagnosis by biopsy
Time frame: 60 months after liver transplantation
Incidence of AKI or CKD
AKI/CKD diagnosed according to KDIGO 2012 AKI and CKD diagnosis criteria
Time frame: 60 months after liver transplantation
Adverse events
Incidence of leukopenia/neutropenia, incidence of viral infections, incidence of new tumors (non-liver cancer).
Time frame: 60 months after liver transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.